Part,  Chapter, Paragraph

 1    I,     2. 10.  1|         development of new genetic tests, DNA chip technologies and
 2   II,     5.  1.  2|          technical dimensions; lab tests, x-rays, hospital care,
 3   II,     5.  5.  3|           more specific diagnostic tests has perhaps contributed
 4   II,     5.  5.  3|            with normal~ diagnostic tests (3 months)~ Sporadic seizures (
 5   II,     5.  5.  3|    outpatient care, drug costs and tests], non-medical costs [services,
 6   II,     5.  5.  3|         There are no pathognomonic tests for the diagnosis of MS.
 7   II,     5.  7.  1|    detected via simple biochemical tests including a creatinine-based
 8   II,     5.  8.  5|         examination, lung function tests, imaging techniques and
 9   II,     5.  9.  4|         allergen to the battery of tests increased the overall estimated
10   II,     5.  9.  4|     sensitization using skin prick tests. However, comparisons between
11   II,     5.  9.  4|       allergen as measured by skin tests was established using the
12   II,     5.  9.  4|          countries, underwent skin tests for allergy to nine common
13   II,     5.  9.  4|       allergen as assessed by skin tests.~ ~Table 5.9.5. High or
14   II,     5.  9.  4|         centre as assessed by skin tests~ ~ ~ ~Centre~d1~e1~g6~m2~
15   II,     5.  9.  4|          allergy skin and in-vitro tests were available. 11.1% suffered
16   II,     5.  9.  4|        ECRHS, underwent skin prick tests and serological assays)
17   II,     5.  9.  4|          target cells. Provocation tests will then be carried out
18   II,     5.  9.  4|         the results of the various tests and to the epidemiological
19   II,     5. 10.  2|  intolerance) and/or sensitization tests (e.g., skin prick tests,
20   II,     5. 10.  2|            tests (e.g., skin prick tests, specific IgE tests) rather
21   II,     5. 10.  2|          prick tests, specific IgE tests) rather than gold standard
22   II,     5. 10.  2|   Questionnaires and sensitization tests tend to overestimate the
23   II,     5. 11.  3|           97 and 200002 the patch tests revealed percentages of
24   II,     5. 11.  3|  development of standardized patch tests, in vitro predictive tests,
25   II,     5. 11.  3|         tests, in vitro predictive tests, in vitro skin absorption
26   II,     5. 12.  2|          on a log scale), and then tests whether one or more joinpoints (
27   II,     5. 12.  7|    Midthune DN (2000): Permutation tests for joinpoint regression
28   II,     6.  3.  1|         need to know the number of tests performed, not just the
29   II,     6.  3.  1|             not just the number of tests found positive.~ ~The annual
30   II,     6.  3.  3|        became rare, as routine HCV tests became more available.~After
31   II,     6.  4.  5|      diagnostic and susceptibility tests. A need has also been identified
32   II,     8.  2.  1|          conditions through simple tests.~ ~Health risks of people
33   II,     8.  2.  1|            to prematurity.~Certain tests, such as ultrasound, amniocentesis,
34   II,     8.  2.  1|        sampling, and various blood tests, can be performed during
35   II,     9.  3.  1|          referred for non-invasive tests, and fewer women than men
36  III,    10.  2.  4|         development of new genetic tests, DNA chip technologies and
37  III,    10.  2.  4|       laboratories can perform the tests. For the multifactorial
38  III,    10.  2.  4| differentiation between predictive tests (i.e., tests with 0-100%
39  III,    10.  2.  4|            predictive tests (i.e., tests with 0-100% probability
40  III,    10.  2.  4|      diseases) on the one hand and tests for diseases with high penetrance (
41  III,    10.  4.  2|             However, the number of tests to be performed is not specified.
42  III,    10.  4.  5|           Under the Directive, the tests for bathing waters have
43  III,    10.  4.  5|        instead of the 19 different tests used previously. This simplification
44  III,    10.  4.  5|        reduced. There will be more tests carried out more frequently
45  III,    10.  4.  5|         show the quality of recent tests. Under this new regime,
46  III,    10.  5.  1|       increased speed at different tests in 10-12 y old pupils (Wargocki
47   IV,    11.  1.  5|            how and when particular tests and treatments should be
48   IV,    11.  5.  3|         carrying out the different tests is a binding requirement
49   IV,    11.  5.  3|  guidelines.~The use of authorised tests for testing the donors is
50   IV,    11.  5.  3|            16 shows the biological tests used in the countries and
51   IV,    11.  5.  3|            indicates whether these tests are carried out on a routine
52   IV,    11.  5.  3|           Figure 11.16. Biological tests in organ transplant~ ~As
53   IV,    11.  5.  3|          in the use of a number of tests (Anti HIV, Anti HCV, Ag-Hbs
54   IV,    11.  5.  3|         this does not apply to all tests (HTLV, Toxoplasmosis or
55   IV,    11.  5.  3|          countries carry out these tests on a routine basis.~ ~Figure
56   IV,    12.  5    |           conducting exercises and tests of, evaluating and revising
57   IV,    12. 10    |     included information about the tests to be performed for the